Know Cancer

or
forgot password

Comparison of Novel PET/CT Imaging Agents and MRS/MRI in Metastatic and High Risk Prostate Cancer: An Inter-SPORE Collaboration


Phase 1
18 Years
N/A
Not Enrolling
Male
Prostate Cancer

Thank you

Trial Information

Comparison of Novel PET/CT Imaging Agents and MRS/MRI in Metastatic and High Risk Prostate Cancer: An Inter-SPORE Collaboration


Inclusion Criteria:



- Males 18 years of age or older

- Patients who have completed staging CT and/or bone scan as part of their routine
workup

- Patients with bulky metastatic prostate cancer who have 5 or more lesions suspicious
for distant metastases as determined by routine CT and/or bone scans that are
untreated by radiation

Exclusion Criteria:

- Patients who are less than 6 weeks post operative for Greenfield filter placement

- Patients with metallic surgical implants including pacemaker implants, cochlear
implants, dentures held in place by magnets imbedded in the gums and aneurysm clips
except those inserted at Mayo and only those inserted after October of 1994 and /or
metal fragments in the body including metal fragments in the eyes

Type of Study:

Interventional

Study Design:

Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic

Outcome Measure:

Test accuracy

Outcome Time Frame:

2 years

Safety Issue:

No

Authority:

United States: Institutional Review Board

Study ID:

8-03

NCT ID:

NCT00987376

Start Date:

November 2003

Completion Date:

September 2009

Related Keywords:

  • Prostate Cancer
  • Prostatic Neoplasms

Name

Location

Mayo Clinic RochesterRochester, Minnesota  55905